CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis

Rachel E Miller1, Phuong B Tran, Rosalina Das

  • 1Department of Internal Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL 60612, USA.

Insights

Monocyte chemoattractant protein-1 (MCP-1) and its receptor (CCR2) are key drivers of osteoarthritis pain. Blocking this pathway in mice reduced pain behaviors and macrophage infiltration in the dorsal root ganglia.

Area of Science:

  • Neuroscience
  • Immunology
  • Rheumatology

Background:

  • Osteoarthritis (OA) is a major cause of chronic joint pain with poorly understood mechanisms.
  • Current OA pain treatments are inadequate, often leading to joint replacement surgery.

Purpose of the Study:

  • To investigate the molecular mechanisms and cellular players involved in osteoarthritis-associated joint pain.
  • To identify key molecules mediating pain in a long-term mouse model of knee OA.

Main Methods:

  • Utilized a surgical mouse model for long-term knee osteoarthritis progression.
  • Longitudinally assessed pain-related behaviors and dorsal root ganglia (DRG) changes.
  • Analyzed monocyte chemoattractant protein-1 (MCP-1/CCL2) and its receptor (CCR2) expression and signaling.

Main Results:

  • MCP-1 and CCR2 were upregulated in DRG, correlating with sustained mechanical allodynia and movement-provoked pain behaviors post-surgery.
  • Mice lacking CCR2 (Ccr2-null) showed reduced duration of mechanical allodynia and lacked movement-provoked pain behaviors, despite joint damage.
  • Macrophage infiltration into the DRG was observed in wild-type mice but absent in Ccr2-null mice, implicating CCR2 in this process.

Conclusions:

  • The MCP-1/CCR2 pathway plays a critical role in the development and maintenance of osteoarthritis pain.
  • Targeting the MCP-1/CCR2 pathway, potentially by inhibiting macrophage infiltration, may offer new therapeutic strategies for OA pain.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Nociception01:44

Nociception

Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...